The all-cash deal adds divesiran, a late-stage-ready rare-disease therapy, to Merck KGaA's pipeline and signals a new wave of RNA therapeutics M&A.

A failed late-stage heart study triggered a swift market punishment, forcing investors and boards to reset timelines and risk.